CASPOFUNGIN ACETATE FOR INJECTION POWDER FOR SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CASPOFUNGIN (CASPOFUNGIN ACETATE)

Disponible des:

SANDOZ CANADA INCORPORATED

Codi ATC:

J02AX04

Designació comuna internacional (DCI):

CASPOFUNGIN

Dosis:

70MG

formulario farmacéutico:

POWDER FOR SOLUTION

Composición:

CASPOFUNGIN (CASPOFUNGIN ACETATE) 70MG

Vía de administración:

INTRAVENOUS

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

ECHINOCANDINS

Resumen del producto:

Active ingredient group (AIG) number: 0144763002; AHFS:

Estat d'Autorització:

CANCELLED PRE MARKET

Data d'autorització:

2018-08-01

Fitxa tècnica

_ _
_Caspofungin Acetate for Injection _
_Page 1 of 53_
PRODUCT MONOGRAPH
PR
CASPOFUNGIN ACETATE FOR INJECTION
50 mg/vial and 70 mg/vial caspofungin (as caspofungin acetate)
Antifungal
Sandoz Canada Inc.
145 Jules-Léger
Boucherville (QC)
J4B 7K8
Date of Revision:
July 17, 2017
Submission Control No: 207225
_ _
_Caspofungin Acetate for Injection _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................25
OVERDOSAGE
................................................................................................................32
ACTION AND CLINICAL PHARMACOLOGY
............................................................32
STORAGE AND STABILITY
..........................................................................................33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
...............................................................................35
PHARMACEUTICAL INFORMATION
..........................................................................35
CLINICAL TRIALS
..........................................................................................................36
DETAILED PHAR